Literature DB >> 27363725

Progressive Temporal Change in Serum SHBG, But Not in Serum Testosterone or Estradiol, Is Associated With Bone Loss and Incident Fractures in Older Men: The Concord Health and Ageing in Men Project.

Benjumin Hsu1,2, Markus J Seibel1, Robert G Cumming1,2,3, Fiona M Blyth2, Vasi Naganathan2, Kerrin Bleicher2, David G Le Couteur1,2, Louise M Waite2, David J Handelsman1.   

Abstract

This study aimed to examine progressive temporal relationships between changes in major reproductive hormones across three waves of a cohort study of older men and (1) changes in bone mineral density (BMD) and (2) incident fractures (any, hip or non-vertebral) over an average of 6 years of follow-up. The CHAMP cohort of men aged 70 years and older were assessed at baseline (2005 to 2007, n = 1705), 2-year follow-up (n = 1367), and 5-year follow-up (n = 958). Serum testosterone (T), dihydrotestosterone (DHT), estradiol (E2), and estrone (E1) (by liquid chromatography-tandem mass spectrometry [LC-MS/MS]), and sex hormone-binding globulin (SHBG), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) (by immunoassay) were measured at all time-points, whereas free testosterone (cFT) was calculated using a well-validated formula. Hip BMD was measured by dual-energy X-ray absorptiometry (DXA) at all three time-points, and fracture data were verified radiographically. Statistical modeling was done using general estimating equations (GEEs). For total hip BMD, univariable analyses revealed inverse associations with temporal changes in serum SHBG, FSH, and LH and positive associations for serum E1 and cFT across the three time-points. In models adjusted for multiple covariables, serum SHBG (β = -0.029), FSH (β = -0.065), LH (β = -0.049), E1 (β = 0.019), and cFT (β = 0.033) remained significantly associated with hip BMD. However for femoral neck BMD, only FSH (β = -0.048) and LH (β = -0.036) remained associated in multivariable-adjusted models. Temporal change in serum SHBG, but not T, E2, or other hormonal variables, was significantly associated with any, nonvertebral or hip fracture incidence in univariable analyses. In multivariable-adjusted models, temporal increase in serum SHBG over time remained associated with any fracture (β = 0.060) and hip fracture (β = 0.041) incidence, but not nonvertebral fracture incidence. These data indicate that a progressive increase in circulating SHBG over time predicts bone loss and fracture risk in older men. Further studies are warranted to further characterize changes in circulating SHBG as a mechanism and/or biomarker of bone health during male ageing.
© 2016 American Society for Bone and Mineral Research. © 2016 American Society for Bone and Mineral Research.

Entities:  

Keywords:  AGING; BONE MINERAL DENSITY; FRACTURE; REPRODUCTIVE HORMONE; SHBG

Mesh:

Substances:

Year:  2016        PMID: 27363725     DOI: 10.1002/jbmr.2904

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  11 in total

1.  Identification of Hip BMD Loss and Fracture Risk Markers Through Population-Based Serum Proteomics.

Authors:  Carrie M Nielson; Jack Wiedrick; Jian Shen; Jon Jacobs; Erin S Baker; Aaron Baraff; Paul Piehowski; Christine G Lee; Arie Baratt; Vladislav Petyuk; Shannon McWeeney; Jeong Youn Lim; Douglas C Bauer; Nancy E Lane; Peggy M Cawthon; Richard D Smith; Jodi Lapidus; Eric S Orwoll
Journal:  J Bone Miner Res       Date:  2017-04-06       Impact factor: 6.741

2.  Genetically Predicted Sex Hormone-Binding Globulin and Bone Mineral Density: A Mendelian Randomization Study.

Authors:  Zihao Qu; Jiuzhou Jiang; Fangkun Yang; Jiawei Huang; Jianqiang Zhao; Shigui Yan
Journal:  Calcif Tissue Int       Date:  2020-10-17       Impact factor: 4.333

Review 3.  Bone health in ageing men.

Authors:  Karel David; Nick Narinx; Leen Antonio; Pieter Evenepoel; Frank Claessens; Brigitte Decallonne; Dirk Vanderschueren
Journal:  Rev Endocr Metab Disord       Date:  2022-07-16       Impact factor: 9.306

Review 4.  Male Hypogonadism and Osteoporosis: The Effects, Clinical Consequences, and Treatment of Testosterone Deficiency in Bone Health.

Authors:  Gary Golds; Devon Houdek; Terra Arnason
Journal:  Int J Endocrinol       Date:  2017-03-16       Impact factor: 3.257

5.  Association between serum estradiol level, sex hormone binding globulin level, and bone mineral density in middle-aged postmenopausal women.

Authors:  Zhongxin Zhu; Jin Zhao; Yanfei Fang; Rongwei Hua
Journal:  J Orthop Surg Res       Date:  2021-10-30       Impact factor: 2.359

6.  The Role of Sex Hormones on Bone Mineral Density, Marrow Adiposity, and Muscle Adiposity in Middle-Aged and Older Men.

Authors:  Li Xu; Qian Zhao; Kai Li; Yong Zhang; Chao Wang; Karen Hind; Ling Wang; Yandong Liu; Xiaoguang Cheng
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-21       Impact factor: 5.555

Review 7.  Thyroid Hormone Abuse in Elite Sports: The Regulatory Challenge.

Authors:  Matti L Gild; Mark Stuart; Roderick J Clifton-Bligh; Audrey Kinahan; David J Handelsman
Journal:  J Clin Endocrinol Metab       Date:  2022-08-18       Impact factor: 6.134

8.  FSH Level and Changes in Bone Mass and Body Composition in Older Women and Men.

Authors:  Karin C Wu; Susan K Ewing; Xiaojuan Li; Sigurður Sigurðsson; Vilmundur Guðnason; Deborah M Kado; Trisha F Hue; Gina N Woods; Annegreet G Veldhuis-Vlug; Eric Vittinghoff; Mone Zaidi; Clifford J Rosen; Thomas Lang; Tiffany Y Kim; Ann V Schwartz; Anne L Schafer
Journal:  J Clin Endocrinol Metab       Date:  2021-09-27       Impact factor: 6.134

9.  Impact of sex hormone-binding globulin on the human phenome.

Authors:  Ryan Arathimos; Louise A C Millard; Joshua A Bell; Caroline L Relton; Matthew Suderman
Journal:  Hum Mol Genet       Date:  2020-07-21       Impact factor: 6.150

10.  Age-related changes in estradiol and longitudinal associations with fat mass in men.

Authors:  Albert Wu; Zumin Shi; Sean Martin; Andrew Vincent; Leonie Heilbronn; Gary Wittert
Journal:  PLoS One       Date:  2018-08-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.